| Literature DB >> 22152107 |
Eva S Vadstrup1, Anne Frølich, Hans Perrild, Eva Borg, Michael Røder.
Abstract
BACKGROUND: Type 2 diabetes can seriously affect patients' health-related quality of life and their self-rated health. Most often, evaluation of diabetes interventions assess effects on glycemic control with little consideration of quality of life. The aim of the current study was to study the effectiveness of group-based rehabilitation versus individual counselling on health-related quality of life (HRQOL) and self-rated health in type 2 diabetes patients.Entities:
Mesh:
Year: 2011 PMID: 22152107 PMCID: PMC3251531 DOI: 10.1186/1477-7525-9-110
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Descriptive characteristics of participants at baseline by group
| Rehabilitation group | Individual group | |
|---|---|---|
| N | 70 | 73 |
| Male/Female | 41/29 (59/41) | 44/29 (60/40) |
| Age, years | 58.5 ± 9.0 | 58.0 ± 10.3 |
| Diabetes duration, | 6.7 (0-37) | 6.4 (0-24) |
| - Newly diagnosed diabetes | 14 (20) | 12 (15) |
| HbA1c, % | 7.9 ± 0.8 | 7.8 ± 0.9 |
| Weight, kg | 96.2 ± 15.2 | 98.2 ± 24.8 |
| Smokers/Ex-smokers | 15/27 (21/39) | 13/36 (18/49) |
| No antidiabetic drugs | 9 (13) | 17 (23) |
| OAD only | 48 (68) | 46 (63) |
| Insulin | 13 (19) | 10 (14) |
| Microalbuminuria | 9 (13) | 14 (19) |
| Macroalbuminuria | 3 (4) | 3 (4) |
| Retinopathy | 4 (6) | 3 (4) |
| Peripheral neuropathy | 28 (40) | 24 (33) |
| Cardiovascular event | 8 (11) | 9 (12) |
Mean ± SD or N (%). OAD: Oral Antidiabetic Drug. Microalbuminuria was defined as a urine Albumin:Creatinine Ratio (ACR) ≥ 2.5 - 25 mg/mmol in men and ≥ 3.5 - 25 mg/mmol in women. Macroalbuminuria: ARC > 25 mg/mmol. Peripheral neuropathy was defined as biothesiometric value > 25 volt. Cardiovascular event: Myocardial infarction, Coronary revascularization, Angina pectoris or Stroke.
Figure 1The study flow shown for HRQOL (Health-related Quality of Life) and self-rated health assessments. Of the 264 patients screened 121 was excluded mainly due to too low HbA1c. Main reasons for missing data after randomisation and during the intervention period were dropout due to time constraints and disappointment with randomisation and lost questionnaires.
SF-36 outcomes at baseline and after 6 months intervention.
| Rehabilitation group | Individual group | |||||
|---|---|---|---|---|---|---|
| Baseline | 6 months | Baseline | 6 months | Model summary‡ (95% CI) | ||
| Physical function | 78 (19) | 83 (18) | 83 (20) | 87 (15) | 1.0 (-4.1 to 6.1) | 0.70 |
| Limitation due to physical problems | 72 (35) | 78 (34) | 73 (37) | 78 (34) | -1.5 (-13.5 to 10.6) | 0.81 |
| Bodily pain | 75 (26) | 76 (26) | 77 (23) | 82 (22) | 3.5 (-5.0 to 12.0) | 0.42 |
| General health | 63 (21) | 68 (19) | 65 (17) | 69 (17) | 0.2 (-5.3 to 5.6) | 0.96 |
| Vitality | 59 (24) | 66 (24) | 63 (23) | 69 (20)¶ | 1.5 (-5.6 to 8.6) | 0.68 |
| Social functioning | 87 (24) | 85 (24) | 89 (17) | 89 (18) | 2.4 (-5.2 to 10.0) | 0.53 |
| Limitation due to emotional problems | 78 (33) | 81 (29) | 74 (39) | 82 (34) | 2.2 (-8.8 to 13.2) | 0.69 |
| Mental health | 77 (19) | 80 (18) | 79 (18) | 82 (16) | 0.9 (-4.5 to 6.2) | 0.74 |
Data are means (SD). Score scale range (0-100). A higher score indicates an improvement. ‡Difference in the change (from baseline to 6 months) of each variable between the two groups, when adjusted for baseline values. §Significance of the difference between groups. ¶ Significant (P < 0.05) difference from baseline to 6 months within the group.
DSC-R outcomes at baseline and after 6 months intervention
| Rehabilitation group | Individual group | |||||
|---|---|---|---|---|---|---|
| Baseline | 6 months | Baseline | 6 months | Model summary‡ (95% CI) | ||
| Hyperglycaemia | 1.4 (1.3) | 1.3 (1.1) | 1.5 (1.1) | 1.2 (1.1)¶ | -0.33 (-0.65 to -0.02) | 0.04 |
| Hypoglycaemia | 1.1 (1.1) | 1.1 (1.1) | 1.0 (1.0) | 0.7 (0.8)¶ | -0.30 (-0.60 to -0.01) | 0.04 |
| Fatigue | 2.1 (1.3) | 1.6 (1.2)¶ | 1.8 (1.2) | 1.5 (1.1)¶ | -0.02 (-0.37 to 0.32) | 0.89 |
| Cognitive | 1.2 (1.1) | 1.1 (1.1) | 1.0 (0.9) | 0.9 (0.8) | -0.12 (-0.36 to 0.12) | 0.33 |
| Pain | 0.6 (0.9) | 0.6 (1.0) | 0.4 (0.8) | 0.5 (1.0) | -0.05 (-0.41 to 0.30) | 0.76 |
| Sensory | 0.7 (0.7) | 0.6 (0.8) | 0.5 (0.7) | 0.5 (0.9) | 0.09 (-0.17 to 0.35) | 0.49 |
| Cardiology | 0.9 (0.9) | 0.6 (0.8)¶ | 0.7 (0.7) | 0.6 (0.7) | 0.13 (-0.09 to 0.35) | 0.23 |
| Vision | 0.6 (0.7) | 0.6 (0.8) | 0.5 (0.8) | 0.5 (0.9) | -0.02 (-0.28 to 0.25) | 0.90 |
| Total | 1.0 (0.6) | 0.9 (0.7) | 0.9 (0.6) | 0.8 (0.6) | -0.04 (-0.21 to 0.13) | 0.61 |
Data are means (SD). Score scale range (0-5). A lower score indicate an improvement. ‡Difference in the change (from baseline to 6 months) of each variable between the two groups, when adjusted for baseline values. §Significance of the difference between groups. ¶ Significant (P < 0.05) difference from baseline to 6 months within the group.